UNC and The Hamner Institutes to collaborate in translational research

Key initial areas of anticipated collaboration include pursuit of new therapies for cancer and respiratory diseases by advancing experimental and computational sciences in drug safety assessment, drug disposition, pharmacogenomics, genomic medicine, nanomedicine, drug delivery and public health.

The scientific and business-development teams at The Hamner Institutes will work with Carolina faculty, including those from the Center for Integrative Chemical Biology and Drug Discovery in the Schools of Pharmacy, Medicine and College of Arts and Sciences, University of North Carolina Kenan-Flagler Business School and the University’s Office of Technology Development to identify, assess and enhance development of new research leads. Together, they will collaboratively pursue a wide array of research grant opportunities from government, industry and non-profit organizations to accelerate development of promising research and technologies that can be licensed out or spun out into the University’s new innovation center.

This new partnership between The Hamner Institutes and the University will also draw upon extensive resources available at the state’s other academic institutions and the North Carolina Biotechnology Center, which supports statewide faculty recruitment, scientific education, economic development and technology development.